Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS

By Tural Deniz   Batur Sebnem   Erdamar Sibel   Akar Emre   Kepil Nuray   Mandel Nil   Serdengeçti Süheyla  

Tumor Biology, Vol. 35, Iss. 2, 2014-02 ,pp. : 1041-1049

Springer Publishing Company

Access to resources Recommend Favorite

Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer

By Soeda Hiroshi   Shimodaira Hideki   Watanabe Mika   Suzuki Takao   Gamoh Makio   Mori Takahiro   Komine Keigo   Iwama Noriyuki   Kato Shunsuke   Ishioka Chikashi  

International Journal of Clinical Oncology, Vol. 18, Iss. 4, 2013-08 ,pp. : 670-677

Springer Publishing Company

Access to resources Recommend Favorite

Identification of KRAS and PIK3CA but not BRAF mutations in patients with gastric cancer

By                

Molecular Medicine Reports, Vol. 12, Iss. 1, 2015-01 ,pp. : 1219-1224

Spandidos Publications

Access to resources Recommend Favorite

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas

By              

Oncology Letters, Vol. 7, Iss. 6, 2014-01 ,pp. : 2019-2022

Spandidos Publications

Access to resources Recommend Favorite

Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

By Nakanishi Ryota   Harada Jun   Tuul Munkhbold   Zhao Yan   Ando Koji   Saeki Hiroshi   Oki Eiji   Ohga Takefumi   Kitao Hiroyuki   Kakeji Yoshihiro   Maehara Yoshihiko  

International Journal of Clinical Oncology, Vol. 18, Iss. 6, 2013-12 ,pp. : 1042-1048

Springer Publishing Company

Access to resources Recommend Favorite